City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.
April 3, 2017 | Travis Marshall
An upcoming phase 1 clinical trial at City of Hope will look at the effects of CAR-T cells programmed to target a protein called CS-1, which is found on myeloma cells.
February 2, 2017 | Letisia Marquez
New study in the Journal of Clinical Oncology concludes that patients with relapsed or treatment-resistant double-hit and/or double-expressor lymphomas didn’t respond as well to the transplantation as diffuse large B-cell lymphoma patients who did not have those types of lymphoma.
January 9, 2017 | Abe Rosenberg
Everything changed when a Hodgkin lymphoma patient joined a Phase II clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.
December 16, 2016 | City of Hope
The long-term strategies offered by City of Hope’s Hematologic Malignancies (HM) Program have dramatically improved the lives of patients with leukemia, lymphoma, Hodgkin’s disease and multiple myeloma.
December 7, 2016 | City of Hope
Numerous clinical trials, which lay the groundwork for novel approaches to lymphoma and multiple myeloma therapies, could ultimately lead to new treatments that improve survival and quality of life for patients with those and other diseases. Additional studies give new insight into best practices for the treatment of various blood cancers.
September 14, 2016 | Leti Marquez
Children with acute lymphoblastic leukemia (ALL) are going into remission at higher rates than ever before - thanks to better treatment that stems from leading-edge clinical trials - but adults with ALL still face significant hurdles in overcoming the disease.